Novel Technologies For In Vivo Imaging (R21/R33)

The summary for the Novel Technologies For In Vivo Imaging (R21/R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Technologies For In Vivo Imaging (R21/R33): Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits Phased Innovation (R21/R33) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -The anticipated number of awards is not known. -This FOA will utilize the NIH Phased Innovation (R21 [Phase I]/R33 [Phase II]) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-06-399, that solicits applications using the R33 grant mechanism. The Phased Innovation (R21/R33) mechanism provides support for a first phase (R21) for technical development and proof-of-principle, and a second phase (R33) for technology application and evaluation of clinical utility. The first phase should produce data to demonstrate the feasibility of the technology or technologies proposed for the second phase, and the second phase should be designed to test whether application of the strategy will provide clinical benefit to a defined set of cancer patients. -For combined R21/R33 applications, the applicant may request an R21 budget period of up to 2 years, with a combined budget guideline for direct costs of up to $275,000 for the maximum 2-year period of the Phase I study. The amount of funds requested and their distribution between the years of the Phase I study should be tailored to the needs of the project, with no more than $200,000 in direct costs allowed in any single year. Although the R33 application has no official budgetary limit, applications requesting $500,000 or more in direct costs in any single year of the grant period require prior approval from the NIH 6 weeks before submission. The total project period for an R21/R33 application submitted in response to this FOA may not exceed 4 years and the R21 phase may not exceed 2 years. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Eligible organizations: For-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of local governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; faith-based or community-based organizations; Indian/Native American Tribal Governments (Federally Recognized); Indian/Native American Tribal Governments (Other than Federally Recognized); and Indian/Native American Tribally Designated Organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research; any eligible PD/PI is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.
Federal Grant Title: Novel Technologies For In Vivo Imaging (R21/R33)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-06-398
Type of Funding: Grant
CFDA Numbers: 93.394
CFDA Descriptions: Cancer Detection and Diagnosis Research
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: May 09, 2006
Creation Date: May 09, 2006
Archive Date: Dec 02, 2006
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments Private institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education City or township governments Independent school districts Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments County governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...
Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensit...
Glioblastoma Therapeutics Network (U19 Clinical Trial Required)
Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinic...
Image-Guided Cancer Interventions (STTR [R41/R42])
An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021